Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 28, 2026, 9:37 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 33 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Sponsor: BioCryst Pharmaceuticals Clear all
Completed Phase 1Phase 2 Interventional

Study of Intravenous BCX-1777 in Relapsed or Refractory Aggressive T-Cell Leukemias or Lymphomas

NCT00035022
View directory record Official record
Conditions
Leukemia, Lymphocytic, Lymphoma
Interventions
BCX-1777
Drug
Lead sponsor
BioCryst Pharmaceuticals
Industry
Eligibility
0 Years and older
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2004
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 12, 2006 · Synced Sep 28, 2026, 9:37 PM EDT
Completed Phase 2 Interventional Results available

Evaluation of the Efficacy and Safety of Peramivir in Subjects With Uncomplicated Acute Influenza.

NCT00419263
View directory record Official record
Conditions
Influenza
Interventions
Peramivir 150 mg, Peramivir 300 mg, Placebo
Drug
Lead sponsor
BioCryst Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
344 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
58
States / cities
Birmingham, Alabama • Jonesboro, Arkansas • Anaheim, California + 45 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2015 · Synced Sep 28, 2026, 9:37 PM EDT
Completed Phase 2 Interventional Results available

A Phase II, Multicenter, Randomized, Placebo -Controlled, Study To Evaluate The Efficacy and Safety Of Intramuscular Peramivir 600 mg In Subjects With Uncomplicated Acute Influenza

NCT00705406
View directory record Official record
Conditions
Acute, Uncomplicated Human Influenza
Interventions
Peramivir, Placebo
Drug
Lead sponsor
BioCryst Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
405 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
67
States / cities
Birmingham, Alabama • Phoenix, Arizona • Jonesboro, Arkansas + 58 more
Source: ClinicalTrials.gov public record
Updated Feb 15, 2015 · Synced Sep 28, 2026, 9:37 PM EDT
Completed Phase 2 Interventional

Phase II Study of Forodesine in Subjects With Chronic Lymphocytic Leukemia (CLL)

NCT00640523
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia (CLL)
Interventions
forodesine HCl
Drug
Lead sponsor
BioCryst Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
8
States / cities
Beverly Hills, California • Los Angeles, California • Indianapolis, Indiana + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2012 · Synced Sep 28, 2026, 9:37 PM EDT
Completed Phase 1Phase 2 Interventional

BCX-1777 in Treating Patients With Refractory Cutaneous T-Cell Lymphoma

NCT00061880
View directory record Official record
Conditions
Lymphoma
Interventions
forodesine hydrochloride
Drug
Lead sponsor
BioCryst Pharmaceuticals
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
3
States / cities
Birmingham, Alabama • Durham, North Carolina • Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 29, 2013 · Synced Sep 28, 2026, 9:37 PM EDT
Completed Phase 2 Interventional Results available

Evaluation of Efficacy and Safety of Peramivir in Adults With Acute Serious or Potentially Life-threatening Influenza

NCT00453999
View directory record Official record
Conditions
Influenza
Interventions
Peramivir 200 mg, Peramivir 400 mg, Oseltamivir
Drug
Lead sponsor
BioCryst Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
137 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
41
States / cities
Mobile, Alabama • Jonesboro, Arkansas • Orange, California + 33 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2015 · Synced Sep 28, 2026, 9:37 PM EDT
Withdrawn No phase listed Observational

Pharmacokinetic Assessment of Peramivir in Hospitalized Adults Undergoing Continuous Renal Replacement Therapy

NCT01146353
View directory record Official record
Conditions
Influenza, Renal Failure
Interventions
Not listed
Lead sponsor
Midwestern University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 19, 2018 · Synced Sep 28, 2026, 9:37 PM EDT
Completed Phase 1 Interventional

BCX-1777 in Treating Patients With Refractory Cancer

NCT00073944
View directory record Official record
Conditions
Cancer
Interventions
forodesine hydrochloride
Drug
Lead sponsor
BioCryst Pharmaceuticals
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated May 29, 2013 · Synced Sep 28, 2026, 9:37 PM EDT
Terminated Phase 3 Interventional Results available

Intramuscular Peramivir in Subjects With Uncomplicated Acute Influenza

NCT00610935
View directory record Official record
Conditions
Influenza
Interventions
Peramivir, Placebo
Drug
Lead sponsor
BioCryst Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
96
States / cities
Millbrook, Alabama • Tuscaloosa, Alabama • Phoenix, Arizona + 80 more
Source: ClinicalTrials.gov public record
Updated Mar 16, 2021 · Synced Sep 28, 2026, 9:37 PM EDT
Active, not recruiting Phase 3 Interventional

A Study of Navenibart in Participants With Hereditary Angioedema

NCT06842823
View directory record Official record
Conditions
Hereditary Angioedema (HAE)
Interventions
navenibart, Placebo
Drug
Lead sponsor
Astria Therapeutics, Inc.
Industry
Eligibility
12 Years and older
Enrollment
157 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
19
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 15 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Sep 28, 2026, 9:37 PM EDT
Withdrawn Phase 3 Interventional

A Study to Evaluate the Efficacy and Safety of Intravenous Peramivir in Subjects With Uncomplicated Influenza.

NCT01224795
View directory record Official record
Conditions
Influenza
Interventions
Peramivir, Placebo Comparator
Drug
Lead sponsor
BioCryst Pharmaceuticals
Industry
Eligibility
12 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
96
States / cities
Birmingham, Alabama • Hot Springs, Arkansas • Jonesboro, Arkansas + 93 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Sep 28, 2026, 9:37 PM EDT
Completed Phase 2 Interventional

Study to Evaluate the Urate-Lowering Activity and Safety of Oral BCX4208 Administered in Subjects With Gout

NCT00985127
View directory record Official record
Conditions
Gout
Interventions
placebo, BCX4208
Drug
Lead sponsor
BioCryst Pharmaceuticals
Industry
Eligibility
18 Years to 69 Years
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
24
States / cities
Scottsdale, Arizona • Tucson, Arizona • Irvine, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2012 · Synced Sep 28, 2026, 9:37 PM EDT
Completed Phase 3 Interventional Results available

Safety, PK and Effectiveness of IV Peramivir in Elderly and Higher Risk Subjects With Uncomplicated Influenza

NCT02635724
View directory record Official record
Conditions
Influenza
Interventions
Peramivir
Drug
Lead sponsor
BioCryst Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
15
States / cities
Brooksville, Florida • Lakeland, Florida • Miami, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Mar 22, 2021 · Synced Sep 28, 2026, 9:37 PM EDT
Terminated Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of IV Peramivir in Addition to Standard of Care Compared to Standard of Care Alone in Adults and Adolescents Who Are Hospitalized Due to Influenza

NCT00958776
View directory record Official record
Conditions
Cough, Sore Throat, Nasal Congestion, Headache, Fever, Seasonal Influenza
Interventions
Peramivir+SOC, Placebo+SOC
Drug
Lead sponsor
BioCryst Pharmaceuticals
Industry
Eligibility
12 Years and older
Enrollment
405 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
60
States / cities
La Mesa, California • Long Beach, California • Modesto, California + 49 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2015 · Synced Sep 28, 2026, 9:37 PM EDT
Completed Phase 1 Interventional

Forodesine (BCX-1777) in Treating Patients With Refractory Stage IIA, Stage IIB, Stage III, Stage IVA, or Stage IVB Cutaneous T-Cell Lymphoma

NCT00098332
View directory record Official record
Conditions
Lymphoma
Interventions
forodesine hydrochloride
Drug
Lead sponsor
BioCryst Pharmaceuticals
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2011
U.S. locations
10
States / cities
Birmingham, Alabama • Hot Springs, Arkansas • Stanford, California + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2013 · Synced Sep 28, 2026, 9:37 PM EDT
Terminated Phase 1 Interventional

A Study of Avoralstat In Participants With Diabetic Macular Edema

NCT07228559
View directory record Official record
Conditions
Diabetic Macular Edema (DME)
Interventions
avoralstat
Drug
Lead sponsor
BioCryst Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
3
States / cities
Sacramento, California • Katy, Texas • The Woodlands, Texas
Source: ClinicalTrials.gov public record
Updated May 10, 2026 · Synced Sep 28, 2026, 9:37 PM EDT
Completed Phase 2Phase 3 Interventional Results available

A Long Term Safety Study of BCX7353 in Hereditary Angioedema

NCT03472040
View directory record Official record
Conditions
Hereditary Angioedema, HAE, Prophylaxis
Interventions
BCX7353
Drug
Lead sponsor
BioCryst Pharmaceuticals
Industry
Eligibility
12 Years and older
Enrollment
387 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
42
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Bentonville, Arkansas + 39 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2023 · Synced Sep 28, 2026, 9:37 PM EDT
Completed Phase 2 Interventional

Repeat-Dose of Forodesine Hydrochloride (BCX-1777) Infusion in Patients With Advanced T-Cell Leukemia

NCT00095381
View directory record Official record
Conditions
Leukemia, T-Cell
Interventions
forodesine hydrochloride (BCX-1777)
Drug
Lead sponsor
BioCryst Pharmaceuticals
Industry
Eligibility
Not listed
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
23
States / cities
Los Angeles, California • Palo Alto, California • Denver, Colorado + 18 more
Source: ClinicalTrials.gov public record
Updated Jan 18, 2012 · Synced Sep 28, 2026, 9:37 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of BCX7353 as an Oral Treatment for the Prevention of Attacks in HAE

NCT03485911
View directory record Official record
Conditions
Hereditary Angioedema, HAE
Interventions
BCX7353 capsules, Placebo oral capsule
Drug
Lead sponsor
BioCryst Pharmaceuticals
Industry
Eligibility
12 Years and older
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
27
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 24 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2023 · Synced Sep 28, 2026, 9:37 PM EDT
Completed Phase 2 Interventional

Study to Evaluate sUA-Lowering Activity, Safety & PK Interaction of Oral BCX4208 & Allopurinol Admin. in Subjects w/Gout

NCT01129648
View directory record Official record
Conditions
Gout
Interventions
Placebo, Allopurinol, BCX4208
Drug
Lead sponsor
BioCryst Pharmaceuticals
Industry
Eligibility
18 Years to 69 Years
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
18
States / cities
Scottsdale, Arizona • Irvine, California • South Miami, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2012 · Synced Sep 28, 2026, 9:37 PM EDT
Completed Phase 2 Interventional

A Randomized, Double-Blind, Dose-Response Study of the Safety and Uric Acid Effects of Oral Ulodesine Added to Allopurinol in Subjects With Gout and Concomitant Moderate Renal Insufficiency

NCT01407874
View directory record Official record
Conditions
Gout, Hyperuricemia, Arthritis, Joint Disease, Renal Insufficiency
Interventions
Placebo, Ulodesine (BCX4208) 5 mg, Ulodesine (BCX4208) 10 mg
Drug
Lead sponsor
BioCryst Pharmaceuticals
Industry
Eligibility
18 Years to 69 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
10
States / cities
Mobile, Alabama • Peoria, Arizona • Irvine, California + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2013 · Synced Sep 28, 2026, 9:37 PM EDT
Completed Phase 1 Interventional

A Study of Peldesine (BCX-34) in HIV-Infected Patients

NCT00002237
View directory record Official record
Conditions
HIV Infections
Interventions
Peldesine
Drug
Lead sponsor
BioCryst Pharmaceuticals
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 28, 2026, 9:37 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Study of the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of BCX17725

NCT06539507
View directory record Official record
Conditions
Netherton Syndrome
Interventions
BCX17725, Placebo
Drug
Lead sponsor
BioCryst Pharmaceuticals
Industry
Eligibility
12 Years to 65 Years
Enrollment
78 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
5
States / cities
Palo Alto, California • San Diego, California • New Haven, Connecticut + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Sep 28, 2026, 9:37 PM EDT
Completed Phase 2Phase 3 Interventional Results available

12-Week Safety and Efficacy Study of BCX4161 as an Oral Prophylaxis Against HAE Attacks

NCT02303626
View directory record Official record
Conditions
Hereditary Angioedema, HAE
Interventions
BCX4161, Placebo
Drug
Lead sponsor
BioCryst Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
25
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Granada Hills, California + 21 more
Source: ClinicalTrials.gov public record
Updated Nov 16, 2025 · Synced Sep 28, 2026, 9:37 PM EDT